Telix Pharmaceuticals Limited (ASX:TLX) has announced that the first patient has been treated in Part 2 of its ProstACT Global Phase 3 clinical trial. The dosing took place at the Australian Prostate Centre in Melbourne, Australia. Part 2 represents the randomized treatment expansion phase …
Artrya Limited (ASX:AYA), a medical technology company commercialising its Salix AI-powered cloud platform, has signed a three-year commercial agreement with Northeast Georgia Health System (NGHS). The deal marks Artrya’s second U.S. commercial customer and follows earlier foundation partner collaborations in the United States.
Shares of Algorae Pharmaceuticals Limited (ASX:1AI) rose 21.4% to 1.7 cents per share on 5 December 2025, following the announcement of independent preclinical validation results for itsAI-driven drug combination prediction platform, AlgoraeOS v1 (AOS1). Conducted at the Victorian Centre for Functional Genomics at the …
Paragon Care Limited (ASX:PGC) has attracted significant analyst support, securing aStrongbuyconsensus rating according to EODHD/Others data, accompanied by a consensus target price ofAUD 0.50. The positive sentiment has been reinforced by Bell Potter Securities (Institutional), which recently issued abuyrating on the stock with a …
Pro Medicus Limited (ASX:PME) is an Australia-based healthcare informatics company providing medical imaging software and related services to hospitals and imaging groups globally. Its Visage 7 product suite includes RIS, PACS, archive, workflow, AI, and e-health applications designed for deployment across on-premise and cloud …
Life360, Inc. (NASDAQ:LIF) (ASX:360), the provider of the market-leading family safety and connection mobile application, has been rated abuyby both Jefferies and Bell Potter Securities. Jefferies assigned a target price of AUD 53, while Bell Potter Securities (institutional) set a target of AUD 52.50. …
Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) reported higher earnings for the first half of the 2026 financial year, covering the six months ended 30 September 2025. The result reflected growth across both Hospital and Homecare product groups alongside improvements ingross margin.
Ramsay Health Care (ASX:RHC) providedshareholderswith an update on itsoperational activityand market environment during its 2025 Annual General Meeting. The company reported moderate year-to-date growth in surgical volumes across Australia and Europe, with non-surgical activity rising at mid-single-digit levels. Several markets continued to experience elevated …
Mesoblast (ASX:MSB) continues to advance the commercial rollout of RYONCIL®, following its U.S. FDA approval in December 2024. As the first FDA-approved allogeneic MSC product, RYONCIL launched commercially in April 2025 and delivered grossrevenueof USD 22M in Q1 FY26. The company expects Q2 FY26 …
Pro Medicus Limited (ASX:PME) announced that its U.S. subsidiary, Visage Imaging Inc., has entered into three new customer contracts with a combined minimum value of AUD 29M. All three agreements will be implemented on a Cloud and Full-Stack model. The company stated that these …